Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction
26 Feb 2018
Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data
23 Feb 2018
Insights from the ORBITA trial
ORBITA is a blinded, multicentre randomised trial of PCI versus a placebo procedure for angina relief. Find more about the findings with 2 editorials recently published in EuroIntervention Journal.
Randomised Trials in FFR and PCI
On this page you will find a list of randomised trials in FFR and PCI published in some of the world's top cardiology and interventional cardiology journals.
OCT Atlas app – The second edition is out!
Developed specifically for the iPad, The Clinical Atlas of OCT offers a rapid and interactive guidance to a systematic and scientifically critical interpretation of OCT images for interventional cardiologists, pathologists, and other physicians, technicians, trainees and research staff.
Supported by an unrestricted educational grant from
Outcomes after angiography with sodium bicarbonate and acetylcysteine
28 Nov 2017
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease
20 Nov 2017
Three-year follow-up of the FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation).
Risk of early adverse events after Clopidogrel discontinuation in patients undergoing short-term Dual Antiplatelet Therapy: An individual participant data analysis
11 Oct 2017
2017 ESC Focused update on Dual Antiplatelet Therapy (DAPT)
04 Sep 2017
As dual antiplatelet therapy (DAPT) seems to have been interventionalists’ close companion since the pioneering studies showing its benefits over oral anticoagulants (OAC) some 20 years ago, the myriad of ensuing studies has led to expanding indications, but has also uncovered the inherent risks of DAPT. In the 2017 Focused Update, the hitherto accumulated evidence is eloquently summarized into a set of recommendations that provide guidance on some of the important questions of an interventional cardiologist's everyday practice: which of the currently available P2Y12 inhibitors should be selected, what is the optimal duration of DAPT and how to manage bleeding complications.